{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:59:13Z","timestamp":1785131953822,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12185-026-04192-4","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:19:25Z","timestamp":1774930765000},"page":"157-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical significance of TP53 mutations in patients with acute myeloid leukemia: the HM-SCREEN-JAPAN 01\/02 study"],"prefix":"10.1007","volume":"124","author":[{"given":"Fumiya","family":"Ogasawara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-0739","authenticated-orcid":false,"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SungGi","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"12","key":"4192_CR1","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","volume":"34","author":"T Herold","year":"2020","unstructured":"Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, et al. Validation and refinement of the revised 2017 European Leukemia Net genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34(12):3161\u201372.","journal-title":"Leukemia"},{"issue":"15","key":"4192_CR2","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Hinai A, Sanders M, Kavelaars F, Rijken M, Gradowska P, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139(15):2347\u201354.","journal-title":"Blood"},{"issue":"18","key":"4192_CR3","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","volume":"7","author":"A Stengel","year":"2023","unstructured":"Stengel A, Meggendorfer M, Walter W, Baer C, Nadarajah N, Hutter S, et al. Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS. Blood Adv. 2023;7(18):5540\u20138.","journal-title":"Blood Adv"},{"issue":"13","key":"4192_CR4","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1182\/bloodadvances.2022009100","volume":"7","author":"A Stengel","year":"2023","unstructured":"Stengel A, Haferlach T, Baer C, Hutter S, Meggendorfer M, Kern W, et al. Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS. Blood Adv. 2023;7(13):2952\u20136.","journal-title":"Blood Adv"},{"issue":"1","key":"4192_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/ng0593-42","volume":"4","author":"D Dittmer","year":"1993","unstructured":"Dittmer D, Pati S, Zambetti G, Chu S, Teresky A, Moore M, et al. Gain of function mutations in p53. Nat Genet. 1993;4(1):42\u20136.","journal-title":"Nat Genet"},{"issue":"3","key":"4192_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"PA Muller","year":"2014","unstructured":"Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304\u201317.","journal-title":"Cancer Cell"},{"issue":"9","key":"4192_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jmcb\/mjaa040","volume":"12","author":"C Zhang","year":"2020","unstructured":"Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020;12(9):674\u201387.","journal-title":"J Mol Cell Biol"},{"issue":"5","key":"4192_CR8","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41418-020-00672-0","volume":"28","author":"F Doffe","year":"2021","unstructured":"Doffe F, Carbonnier V, Tissier M, Leroy B, Martins I, Mattson J, et al. Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene. Cell Death Differ. 2021;28(5):1477\u201392.","journal-title":"Cell Death Differ"},{"issue":"13","key":"4192_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1200\/JCO.21.02014","volume":"40","author":"M Pan","year":"2022","unstructured":"Pan M, Jiang C, Tse P, Achacoso N, Alexeeff S, Solorzano A, et al. TP53 gain-of-function and non\u2013gain-of-function mutations are differentially associated with sidedness-dependent prognosis in metastatic colorectal cancer. J Clin Oncol. 2022;40(13):171\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4192_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"4192_CR11","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","volume":"6","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber D, Cin P, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML. Blood Adv. 2022;6(9):2847\u201353.","journal-title":"Blood Adv"},{"issue":"11","key":"4192_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Hasserjian RP, Borowitz MJ, Caivo KR, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328.","journal-title":"Blood"},{"issue":"6","key":"4192_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson M, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536\u201347.","journal-title":"N Engl J Med"},{"issue":"17","key":"4192_CR14","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","volume":"129","author":"T Yoshizato","year":"2017","unstructured":"Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Yamashita Y, Yoshida K, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129(17):2347\u201358.","journal-title":"Blood"},{"issue":"8","key":"4192_CR15","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier B, Maloney D, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912\u20139.","journal-title":"Blood"},{"issue":"3","key":"4192_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","volume":"8","author":"MT Nawas","year":"2024","unstructured":"Nawas MT, Kosuri S. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML. Blood Adv. 2024;8(3):553\u201361.","journal-title":"Blood Adv"},{"issue":"6453","key":"4192_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365(6453):599\u2013604.","journal-title":"Science"},{"issue":"3","key":"4192_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/leu.2015.304","volume":"30","author":"DA Sallman","year":"2016","unstructured":"Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer S, McGraw K, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30(3):666\u201373.","journal-title":"Leukemia"},{"issue":"22","key":"4192_CR19","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","volume":"4","author":"NJ Short","year":"2020","unstructured":"Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz M, Kanagal-Shamanna R, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4(22):5681\u20139.","journal-title":"Blood Adv"},{"issue":"10","key":"4192_CR20","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549\u201356.","journal-title":"Nat Med"},{"issue":"1","key":"4192_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-023-01480-y","volume":"16","author":"W Bahaj","year":"2023","unstructured":"Bahaj W, Kewan T, Gurnari C, Durmaz A, Ponvilawan B, Pandit I, et al. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia. J Hematol Oncol. 2023;16(1):91.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4192_CR22","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/sj.cdd.4401910","volume":"13","author":"AJ Levine","year":"2006","unstructured":"Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored. Cell Death Differ. 2006;13(6):1027\u201336.","journal-title":"Cell Death Differ"},{"issue":"1","key":"4192_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/ncb2641","volume":"15","author":"PA Muller","year":"2013","unstructured":"Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol. 2013;15(1):2\u20138.","journal-title":"Nat Cell Biol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04192-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:04:37Z","timestamp":1785128677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04192-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4192"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04192-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.F.\n                      : Janssen: Honoraria.\n                      Y.M.:\n                      Daiichi Sankyo: Honoraria, Research Funding; Taiho Pharmaceutical: Research Funding; Tejin Pharma: Research Funding; Takeda: Research Funding; Sumitomo Pharma Oncology: Research Funding; Shionogi: Research Funding; Sanofi: Research Funding; Otsuka: Research Funding; Nippon Shinyaku: Research Funding; Nihonkayaku: Research Funding; Kyowa Hakko Kirin: Research Funding; Dainippon Sumitomo Pharma: Research Funding; Asahi Kasei: Research Funding; Taiho Pharmaceutical: Honoraria; Shinogi: Honoraria; Sanofi: Honoraria; Otsuka: Honoraria; Ono Pharmaceutical: Honoraria; Merck: Honoraria; Meiji Seika Kaisha: Honoraria; Lilly: Honoraria, Research Funding; Kyowa Hakko Kirin: Honoraria; Eisai: Honoraria, Research Funding; Chugai Pharma: Honoraria, Research Funding; Bayer: Honoraria, Research Funding; Abbvie: Honoraria; Pfizer Japan Inc.: Honoraria; Bristol-Myers Squibb Company: Honoraria; Takeda: Honoraria; Novartis Pharma KK: Honoraria.\n                      K.K.:\n                      Pfizer Japan, Inc., Takeda: Honoraria. The remaining authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the institutional review board at each center and carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}